next gen ACLY inhibitor (Esperion Therapeutics)

N/A

Report date: 2025/06/11 10:55:24
NME

Base Information

Drug Namenext gen ACLY inhibitor (Esperion Therapeutics)
Drug Alias Namenext gen ATP-citrate lyase inhibitor (Esperion Therapeutics)
ClassificationSmall molecules
Mechanisms of ActionATP-citrate synthase inhibitors
TargetsATP-citrate synthase
Therapy Area/IndicationsKidney Failure, ChronicPolycystic Kidney, Autosomal Dominant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEsperion Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEsperion Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsKidney Failure, ChronicPolycystic Kidney, Autosomal Dominant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A